These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 25052122

  • 1. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN, Clinard VB, Woodis CB.
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT, Kao CJ, DeGregorio MW.
    Clin Interv Aging; 2014 Oct; 9():1939-50. PubMed ID: 25419123
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J, Portman D, Mabey RG, Ospemifene Study Group.
    Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA, Komi JO, Ospemifene Study Group.
    Menopause; 2010 Mar; 17(3):480-6. PubMed ID: 20032798
    [Abstract] [Full Text] [Related]

  • 6. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group.
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G, Graham S, Koltun WD, Kingsberg SA.
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [Abstract] [Full Text] [Related]

  • 13. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN, Pearce EF, Yancey AM, Forinash AB.
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [Abstract] [Full Text] [Related]

  • 14. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV, Stanczyk FZ.
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [Abstract] [Full Text] [Related]

  • 15. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J.
    Climacteric; 2016 Mar; 19(1):60-5. PubMed ID: 26669628
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
    Cui Y, Zong H, Yan H, Li N, Zhang Y.
    J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
    Reid RL, Black D, Derzko C, Portman D.
    J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.